Memantine Hydrochloride Tablet
Product Images NDC 71335-1732

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 71335-1732). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 01)

Chemical structure diagram showing the molecular structure of Memantine Hydrochloride with labeled functional groups, including NH2 and HCl, and methyl groups attached to the ring system.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 02)

A line graph comparing the mean change from baseline in ADCS-ADL score over 28 weeks of treatment with Memantine Hydrochloride (M.HCl) versus placebo. The x-axis shows weeks of treatment (0, 4, 12, 28), and the y-axis shows mean change from baseline with clinical improvement and decline indicated. Memantine shows less decline compared to placebo over time.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 03)

A cumulative percentage of patients chart comparing the effects of Memantine Hydrochloride (M.HCl) versus placebo. The x-axis represents ADCS-ADL change from baseline, while the y-axis shows the cumulative percentage of patients, indicating how patients respond to treatment in terms of ADCS-ADL score changes.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 04)

A line graph showing the mean change from baseline in SIB Score over 28 weeks of treatment for Memantine Hydrochloride (M.HCl) and placebo groups. The y-axis represents mean change with standard error, ranging from clinical improvement to clinical decline, and the x-axis shows weeks of treatment. M.HCl shows a stable or slight improvement trend, while placebo shows a steady decline over time.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 05)

A line graph comparing the cumulative percentage of patients against the SIB (Severe Impairment Battery) change from baseline. Two groups are depicted: one with Memantine Hydrochloride labeled as 'M. HCl' represented by circles, and the other with placebo represented by squares. The graph shows a trend where Memantine Hydrochloride group generally has a greater negative change from baseline compared to placebo.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 06)

A line graph showing mean ± SEM change from baseline in ADCS-ADL score over 24 weeks of treatment. Two treatment groups are compared: Placebo/Donepezil (black squares) and Memantine Hydrochloride/Donepezil (open circles). The graph depicts clinical improvement and decline with points plotted at 0, 4, 8, 12, 16, 20, and 24 weeks. Memantine Hydrochloride/Donepezil shows less decline than Placebo/Donepezil over time.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 07)

A cumulative percentage of patients graph showing ADCS-ADL change from baseline. The x-axis represents ADCS-ADL change from baseline ranging roughly from +15 to -25, and the y-axis shows the cumulative percentage of patients from 0 to 100%. Two curves are compared: one for Placebo/Donepezil (black squares) and one for Memantine Hydrochloride (M. HCl)/Donepezil (open circles). The graph illustrates patient response distribution over the change in ADCS-ADL scores.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 08)

Line chart showing mean change from baseline in SIB score over 24 weeks of treatment. Two groups are compared: Placebo/Donepezil and Memantine Hydrochloride (M.HCl)/Donepezil. The vertical axis represents mean change with error bars, while the horizontal axis shows weeks of treatment. Clinical improvement is indicated above the baseline line; clinical decline below.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 09)

A cumulative percentage graph comparing patients' SIB (Severe Impairment Battery) change from baseline between two groups: Placebo/Donepezil and Memantine Hydrochloride/Donepezil. The x-axis shows SIB change from baseline, and the y-axis shows the cumulative percentage of patients, with two plotted lines representing each group.*

FDA Label Image

Label (Lbl713351732)

Label for Memantine HCl 5 mg Tablet, an oral prescription drug by Bryant Ranch Prepack. The label indicates a 30-count package, includes storage instructions at 20°-25°C (68°-77°F), and a warning to keep out of children's reach. The label references a comparison to Namenda 5 mg tablet by Cadila Healthcare Ltd and shows the NDC 71335-1732.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.